Therapie der akuten und chronischen Herzinsuffizienz mit Herzglykosiden

Erdmann, Erland

doi:10.1007/978-3-642-82183-7_15

Cited by 2 publications

(2 citation statements)

References 385 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In several trials, it was demonstrated that treatment with the selective β 1 -receptor antagonists bisoprolol and metoprolol, and with the nonselective αand β-receptor antagonist carvedilol, improves cardiac function and increases life expectancy in patients with heart failure [5]. The third group of substances, which serve as neurohormonal blockers and have been demonstrated to lead to a decrease in morbidity and mortality when used in the treatment of heart failure, are aldosterone antagonists [6,7].…”

Section: Markus Flesch MD and Erland Erdmann Md Fesc Faccmentioning

confidence: 99%

The problem of polypharmacy in heart failure

Flesch¹,

Erdmann

2006

Curr Cardiol Rep

View full text Add to dashboard Cite

Improvements in the medical therapy for chronic heart failure have led to a dramatic decrease in the morbidity and mortality of patients with heart failure over the past two decades. This improvement has been gained at the expense of an increasing number of potent drugs that heart failure patients have to take chronically. Because heart failure forms the end-stage of different cardiovascular diseases and their predisposing risk factors, patients need drug treatment not only for heart failure itself but also for related conditions. Even more, because most heart failure patients are elderly, a number of unrelated, noncardiovascular diseases become apparent, which further increase the number of pharmaceutical substances with which heart failure patients are treated. The resulting polypharmacy leads to problems including economic burden, patient compliance, and most importantly, partly unpredictable drug interactions. This article reviews the existing data concerning some of these problems, to provide an aid for choosing the appropriate drugs in heart failure patients and minimizing the patient's risk.

show abstract

Section: Markus Flesch MD and Erland Erdmann Md Fesc Faccmentioning

confidence: 99%

The problem of polypharmacy in heart failure

Flesch¹,

Erdmann

2006

Curr Cardiol Rep

View full text Add to dashboard Cite

show abstract

“…14) Wie insbesondere fUr die "Chemisch-physlkalische, und pharma-zeutischS' Pensionsanstalt fur Junglinge" in Er. :furt des Apothekers Johann Bartholomaus Trommsdorff (1770 -1837) 15) und fur das Institut Heinrich Wackenroders (1798 -1854) Instabilitat der 6-Hydroxyverbindung (7), die zur Bildung der Syntheseausgangsverbindung 3-Amino-l,2,4-triazol (8) pur die chronische Therapie der Herzinsuffizienz wird wegen der engen therapeutischen Breite der Herzglykoside seit langem nach anderen positiv inotropen Substanzen gesucht (Scholz 1984, colucci et ale 1986, Erdmann 1986, LeJemtel et ale 1986, Packer 1988a, Robertson und Hayes 1986, Bleifeld und Storstein 1989, v. der Leyen 1989, Ravens 1989 Therapie der Herzinsuffizienz durchsetzen werden (Colucci et ale 1986, LeJemtel et ale 1986, Packer 1988a, Packer 1988b (Bristow et a1. 1982, Brodde et a1.…”

unclassified

Plenarvorträge

1991

Archiv der Pharmazie

View full text Add to dashboard Cite

Therapie der akuten und chronischen Herzinsuffizienz mit Herzglykosiden

Cited by 2 publications

References 385 publications

The problem of polypharmacy in heart failure

The problem of polypharmacy in heart failure

Plenarvorträge

Contact Info

Product

Resources

About